References

Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC—mechanisms and evolving treatment approaches

10.1038/s41571-025-01085-z · 2026 · External reference

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

10.1016/j.annonc.2023.10.117 · 2024 · External reference

Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial

10.1001/jama.2024.10613 · 2024 · External reference

Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC

10.1056/nejmoa2512071 · 2026 · External reference

Unresolved reference

2026 · External reference

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

10.1038/s41591-023-02554-7 · 2023 · External reference

10.1016/s2213-2600(23)00135-2

10.1016/s2213-2600(23)00135-2 · 2023 · External reference

Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer

10.1200/jco.23.02747 · 2024 · External reference

Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)

10.1200/jco.23.01891 · 2024 · External reference

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial

10.1016/s0140-6736(25)01811-2 · 2026 · External reference